Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists

Patent metadata

Field	Value
Publication number	US-11046774-B2
Application number	US-201916285118-A
Country	US
Kind code	B2
Filing date	Feb 25, 2019
Priority date	Dec 23, 2015
Publication date	Jun 29, 2021
Grant date	Jun 29, 2021

Abstract

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

First claim

What is claimed is:

1. A method of treating a subject with a metabolic disorder, the method comprising administering to the subject a therapeutically effective amount of an antigen binding protein that specifically binds to a polypeptide comprising amino acids 1-139 of human Gastric Inhibitory Peptide Receptor (“GIPR”), wherein said antigen binding protein is an antibody and is an antagonist of GIPR.

2. The method of claim 1 , wherein said metabolic disorder is a disorder of glucose metabolism.

3. The method of claim 2 , wherein said glucose metabolism disorder comprises hyperglycemia and wherein said administering reduces plasma glucose in said subject.

4. The method of claim 2 , wherein said glucose metabolism disorder comprises hyperinsulinemia and wherein said administering reduces plasma insulin in said subject.

5. The method of claim 2 , wherein said glucose metabolism disorder comprises glucose intolerance and wherein said administering increases glucose tolerance in said subject.

6. The method of claim 2 , wherein said disorder of glucose metabolism comprises insulin resistance and wherein said administering decreases insulin resistance in said subject.

7. The method of claim 2 , wherein said glucose metabolism disorder comprises diabetes mellitus.

8. The method of claim 2 , wherein said subject is obese.

9. The method of claim 8 , wherein said administering reduces body weight in said subject.

10. The method of claim 8 , wherein said administering reduces body weight gain in said subject.

11. The method of claim 8 , where said administering reduces fat mass in said subject.

12. The method of claim 8 , wherein said disorder of glucose metabolism comprises insulin resistance and wherein said administering reduces insulin resistance in said subject.

13. The method of claim 8 , wherein said subject has increased liver steatosis, and wherein said administering reduces liver steatosis in said subject.

14. The method of claim 8 , wherein said subject has increased liver fat content, and wherein said administering reduces liver fat content in said subject.

15. The method of claim 1 , wherein said subject is a mammal.

16. The method of claim 1 , wherein said subject is human.

17. The method of claim 1 , wherein said administering is by parenteral injection.

18. The method of claim 1 , wherein said administering is by subcutaneous injection.

Assignees

• Amgen Inc

Inventors

• Yie Junming
• Shi Donghui
• Lloyd David J
• Wang Jinghong
• Sivits Jr Glenn N
• Veniant-Ellison Murielle M
• Komorowski Renee
• Agrawal Neeraj
• Bates Darren L
• Clavette Brandon C P
• Foltz Ian N
• Ho Shu-Yin
• Murawsky Christopher
• Min Xiaoshan
• Wang Zhulun

Classifications

• A61P3/08

  for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61K38/1703

  from vertebrates · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title